Craig Friesen
Concepts (388)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dyspepsia | 25 | 2021 | 48 | 8.900 |
Why?
| Abdominal Pain | 27 | 2023 | 72 | 6.390 |
Why?
| Gastrointestinal Diseases | 15 | 2023 | 55 | 5.150 |
Why?
| Eosinophilia | 12 | 2022 | 21 | 4.400 |
Why?
| Irritable Bowel Syndrome | 8 | 2023 | 21 | 4.060 |
Why?
| Intestinal Mucosa | 10 | 2021 | 36 | 3.460 |
Why?
| Eosinophils | 16 | 2022 | 29 | 3.420 |
Why?
| Mast Cells | 13 | 2022 | 23 | 3.410 |
Why?
| Adolescent | 58 | 2023 | 2137 | 3.280 |
Why?
| Child | 69 | 2023 | 3257 | 3.250 |
Why?
| Male | 64 | 2022 | 3328 | 2.890 |
Why?
| Humans | 88 | 2023 | 6797 | 2.850 |
Why?
| Female | 64 | 2022 | 3599 | 2.820 |
Why?
| Food Hypersensitivity | 5 | 2023 | 17 | 2.400 |
Why?
| Inflammatory Bowel Diseases | 5 | 2019 | 42 | 1.950 |
Why?
| Gastric Mucosa | 6 | 2021 | 14 | 1.950 |
Why?
| Inflammation | 7 | 2022 | 51 | 1.690 |
Why?
| Depression | 5 | 2021 | 68 | 1.600 |
Why?
| Duodenum | 7 | 2022 | 20 | 1.580 |
Why?
| Retrospective Studies | 20 | 2023 | 1332 | 1.530 |
Why?
| Urinary Bladder, Overactive | 2 | 2023 | 5 | 1.520 |
Why?
| Gastric Emptying | 5 | 2019 | 9 | 1.500 |
Why?
| Anxiety | 4 | 2021 | 46 | 1.460 |
Why?
| Heart Rate | 4 | 2020 | 26 | 1.340 |
Why?
| Antibodies, Monoclonal | 4 | 2013 | 23 | 1.250 |
Why?
| Gastritis | 4 | 2020 | 8 | 1.240 |
Why?
| Gastroenterology | 2 | 2022 | 17 | 1.210 |
Why?
| Chronic Pain | 5 | 2021 | 31 | 1.160 |
Why?
| Carbohydrate Metabolism, Inborn Errors | 3 | 2021 | 3 | 1.150 |
Why?
| Autonomic Nervous System | 3 | 2020 | 8 | 1.140 |
Why?
| Esophagitis | 4 | 2020 | 7 | 1.080 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2015 | 17 | 1.080 |
Why?
| Enterocolitis | 3 | 2015 | 37 | 1.030 |
Why?
| Gastroesophageal Reflux | 6 | 2018 | 45 | 1.010 |
Why?
| Sleep Wake Disorders | 3 | 2021 | 18 | 1.000 |
Why?
| Gastroparesis | 2 | 2019 | 5 | 0.970 |
Why?
| Child, Preschool | 19 | 2022 | 1503 | 0.960 |
Why?
| Lactase | 2 | 2021 | 2 | 0.960 |
Why?
| Urination Disorders | 1 | 2023 | 4 | 0.950 |
Why?
| Urinary Bladder Diseases | 1 | 2023 | 3 | 0.950 |
Why?
| Colon | 2 | 2021 | 13 | 0.940 |
Why?
| Tick Bites | 1 | 2023 | 1 | 0.940 |
Why?
| Th17 Cells | 2 | 2020 | 5 | 0.930 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 31 | 0.930 |
Why?
| Surveys and Questionnaires | 10 | 2022 | 297 | 0.930 |
Why?
| Anaphylaxis | 1 | 2023 | 9 | 0.920 |
Why?
| Biopsy | 8 | 2022 | 59 | 0.900 |
Why?
| Cell Count | 7 | 2022 | 17 | 0.880 |
Why?
| Emergency Medical Services | 1 | 2022 | 14 | 0.850 |
Why?
| Headache | 2 | 2020 | 15 | 0.840 |
Why?
| Colonic Diseases | 1 | 2021 | 5 | 0.810 |
Why?
| Heartburn | 1 | 2021 | 2 | 0.810 |
Why?
| Acetates | 3 | 2009 | 5 | 0.780 |
Why?
| Quinolines | 3 | 2009 | 6 | 0.780 |
Why?
| Leukotriene Antagonists | 3 | 2009 | 6 | 0.780 |
Why?
| Duodenitis | 3 | 2021 | 4 | 0.770 |
Why?
| Psychophysiologic Disorders | 1 | 2020 | 3 | 0.760 |
Why?
| Intestine, Large | 1 | 2020 | 1 | 0.760 |
Why?
| Nausea | 1 | 2020 | 16 | 0.750 |
Why?
| Drinking | 3 | 2009 | 6 | 0.750 |
Why?
| Pediatrics | 2 | 2014 | 175 | 0.740 |
Why?
| Cold Temperature | 1 | 2019 | 2 | 0.730 |
Why?
| Gastrointestinal Motility | 1 | 2019 | 7 | 0.730 |
Why?
| Stress, Physiological | 1 | 2019 | 9 | 0.720 |
Why?
| Capsule Endoscopy | 1 | 2019 | 4 | 0.720 |
Why?
| Ileum | 1 | 2019 | 18 | 0.710 |
Why?
| Cross-Sectional Studies | 6 | 2021 | 319 | 0.700 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 116 | 0.670 |
Why?
| Gastrointestinal Tract | 1 | 2018 | 7 | 0.670 |
Why?
| Eating | 2 | 2009 | 31 | 0.660 |
Why?
| Tooth Erosion | 1 | 2017 | 1 | 0.630 |
Why?
| Duodenal Diseases | 2 | 2010 | 4 | 0.620 |
Why?
| Intestines | 2 | 2015 | 26 | 0.620 |
Why?
| Endoscopy, Digestive System | 4 | 2022 | 8 | 0.620 |
Why?
| Immunoglobulin E | 2 | 2023 | 22 | 0.610 |
Why?
| Esophagus | 5 | 2017 | 32 | 0.590 |
Why?
| Electromyography | 3 | 2020 | 6 | 0.560 |
Why?
| Age Factors | 5 | 2021 | 215 | 0.550 |
Why?
| Severity of Illness Index | 7 | 2019 | 144 | 0.540 |
Why?
| Infant | 17 | 2022 | 1449 | 0.530 |
Why?
| Pyloric Antrum | 2 | 2020 | 4 | 0.520 |
Why?
| Diarrhea | 4 | 2023 | 18 | 0.510 |
Why?
| Chronic Disease | 10 | 2020 | 104 | 0.500 |
Why?
| Stomach | 4 | 2015 | 15 | 0.500 |
Why?
| Primary Health Care | 1 | 2014 | 44 | 0.490 |
Why?
| Prospective Studies | 8 | 2019 | 522 | 0.490 |
Why?
| Quality of Life | 3 | 2023 | 134 | 0.490 |
Why?
| Crohn Disease | 5 | 2020 | 22 | 0.480 |
Why?
| Somatoform Disorders | 2 | 2010 | 6 | 0.470 |
Why?
| Treatment Outcome | 8 | 2019 | 667 | 0.470 |
Why?
| Postprandial Period | 5 | 2020 | 14 | 0.460 |
Why?
| Practice Patterns, Physicians' | 2 | 2014 | 85 | 0.460 |
Why?
| Electrocardiography | 3 | 2020 | 13 | 0.450 |
Why?
| Relaxation Therapy | 3 | 2019 | 6 | 0.440 |
Why?
| Pain Measurement | 5 | 2019 | 45 | 0.430 |
Why?
| Avoidance Learning | 2 | 2022 | 6 | 0.420 |
Why?
| Cromolyn Sodium | 2 | 2006 | 3 | 0.410 |
Why?
| Biofeedback, Psychology | 1 | 2010 | 3 | 0.380 |
Why?
| Emergency Service, Hospital | 3 | 2022 | 130 | 0.370 |
Why?
| Risk Factors | 3 | 2021 | 470 | 0.370 |
Why?
| Case-Control Studies | 5 | 2018 | 205 | 0.370 |
Why?
| Myoelectric Complex, Migrating | 2 | 2006 | 4 | 0.370 |
Why?
| Acetaminophen | 2 | 2019 | 18 | 0.340 |
Why?
| Electrophysiology | 1 | 2008 | 5 | 0.330 |
Why?
| Self Report | 3 | 2021 | 43 | 0.320 |
Why?
| Gastrointestinal Agents | 2 | 2004 | 5 | 0.320 |
Why?
| Prevalence | 6 | 2018 | 149 | 0.310 |
Why?
| Animals | 4 | 2023 | 664 | 0.300 |
Why?
| United States | 3 | 2019 | 656 | 0.290 |
Why?
| Histamine Antagonists | 1 | 2006 | 8 | 0.280 |
Why?
| Sleep | 4 | 2020 | 36 | 0.280 |
Why?
| Adult | 9 | 2021 | 1259 | 0.280 |
Why?
| Cystic Fibrosis | 2 | 1995 | 18 | 0.260 |
Why?
| Fear | 2 | 2022 | 17 | 0.260 |
Why?
| Prognosis | 2 | 2021 | 213 | 0.260 |
Why?
| Cytokines | 2 | 2018 | 48 | 0.250 |
Why?
| Technetium Tc 99m Sulfur Colloid | 2 | 2019 | 3 | 0.250 |
Why?
| Radionuclide Imaging | 2 | 2019 | 5 | 0.250 |
Why?
| Time Factors | 5 | 2019 | 247 | 0.240 |
Why?
| Pilot Projects | 4 | 2019 | 128 | 0.240 |
Why?
| Mammals | 1 | 2023 | 3 | 0.240 |
Why?
| Constipation | 2 | 2021 | 16 | 0.230 |
Why?
| Breath Tests | 2 | 2020 | 11 | 0.230 |
Why?
| Brain | 1 | 2023 | 82 | 0.220 |
Why?
| Diagnostic Techniques and Procedures | 1 | 2022 | 4 | 0.220 |
Why?
| Postpartum Period | 2 | 1999 | 8 | 0.220 |
Why?
| Lactation | 2 | 1999 | 7 | 0.220 |
Why?
| Breast Feeding | 2 | 1999 | 23 | 0.210 |
Why?
| Sensitivity and Specificity | 3 | 2019 | 147 | 0.210 |
Why?
| Feeding and Eating Disorders | 1 | 2022 | 9 | 0.210 |
Why?
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 24 | 0.210 |
Why?
| Models, Psychological | 1 | 2021 | 8 | 0.200 |
Why?
| Disaccharidases | 1 | 2021 | 1 | 0.200 |
Why?
| Colonoscopy | 1 | 2021 | 15 | 0.200 |
Why?
| Infliximab | 3 | 2013 | 7 | 0.200 |
Why?
| Sulfides | 3 | 2009 | 6 | 0.200 |
Why?
| Cyclopropanes | 3 | 2009 | 7 | 0.200 |
Why?
| Sucrase | 1 | 2020 | 1 | 0.190 |
Why?
| Monitoring, Physiologic | 4 | 1994 | 24 | 0.190 |
Why?
| Comorbidity | 2 | 2019 | 64 | 0.190 |
Why?
| Follow-Up Studies | 3 | 2019 | 327 | 0.190 |
Why?
| Helicobacter pylori | 1 | 2020 | 4 | 0.190 |
Why?
| Helicobacter Infections | 1 | 2020 | 4 | 0.190 |
Why?
| Meals | 1 | 2020 | 13 | 0.190 |
Why?
| Affect | 1 | 2020 | 11 | 0.180 |
Why?
| Electromagnetic Phenomena | 1 | 2019 | 2 | 0.180 |
Why?
| Cholecystitis | 1 | 2019 | 6 | 0.180 |
Why?
| Pain Clinics | 1 | 2019 | 2 | 0.180 |
Why?
| Patient Care Team | 1 | 2019 | 19 | 0.180 |
Why?
| Radiopharmaceuticals | 1 | 2019 | 3 | 0.180 |
Why?
| Genes, Regulator | 1 | 2019 | 4 | 0.170 |
Why?
| Hepatocytes | 1 | 2019 | 6 | 0.170 |
Why?
| Milk Hypersensitivity | 2 | 2015 | 3 | 0.170 |
Why?
| Cost Savings | 1 | 2019 | 10 | 0.170 |
Why?
| Gastroenteritis | 1 | 1999 | 25 | 0.170 |
Why?
| Midwestern United States | 2 | 2016 | 43 | 0.170 |
Why?
| Women, Working | 1 | 1999 | 1 | 0.170 |
Why?
| CRISPR-Cas Systems | 1 | 2019 | 13 | 0.170 |
Why?
| Inpatients | 1 | 2019 | 45 | 0.170 |
Why?
| Patient Compliance | 1 | 2019 | 71 | 0.170 |
Why?
| Social Support | 1 | 1999 | 38 | 0.170 |
Why?
| Proton Pump Inhibitors | 1 | 2018 | 13 | 0.170 |
Why?
| Statistics as Topic | 1 | 2018 | 18 | 0.170 |
Why?
| Body Weight | 1 | 2018 | 56 | 0.170 |
Why?
| Protective Agents | 1 | 2018 | 3 | 0.170 |
Why?
| Mandibular Neoplasms | 1 | 2018 | 2 | 0.160 |
Why?
| Osteosclerosis | 1 | 2018 | 2 | 0.160 |
Why?
| Dentofacial Deformities | 1 | 2018 | 2 | 0.160 |
Why?
| Osteoma | 1 | 2018 | 3 | 0.160 |
Why?
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 8 | 0.160 |
Why?
| Analgesics, Non-Narcotic | 1 | 2018 | 8 | 0.160 |
Why?
| Pain Management | 1 | 2018 | 26 | 0.160 |
Why?
| Adenomatous Polyposis Coli Protein | 1 | 2018 | 5 | 0.160 |
Why?
| Cholelithiasis | 2 | 2006 | 7 | 0.160 |
Why?
| Infant, Newborn | 7 | 2022 | 828 | 0.160 |
Why?
| Combined Modality Therapy | 2 | 2010 | 53 | 0.160 |
Why?
| Exercise | 1 | 2019 | 125 | 0.160 |
Why?
| Adenomatous Polyposis Coli | 1 | 2018 | 25 | 0.160 |
Why?
| Oral Hygiene | 1 | 2017 | 3 | 0.160 |
Why?
| Esophagoscopy | 1 | 2017 | 12 | 0.160 |
Why?
| Referral and Consultation | 2 | 2019 | 33 | 0.150 |
Why?
| Diet | 1 | 2017 | 55 | 0.150 |
Why?
| Pain | 4 | 2022 | 53 | 0.150 |
Why?
| Hydrogen-Ion Concentration | 5 | 1995 | 20 | 0.150 |
Why?
| Receptors, Steroid | 1 | 2016 | 4 | 0.140 |
Why?
| Bilirubin | 2 | 2022 | 25 | 0.140 |
Why?
| Analysis of Variance | 3 | 2012 | 28 | 0.140 |
Why?
| Intestine, Small | 1 | 2016 | 15 | 0.140 |
Why?
| Milk Proteins | 1 | 2015 | 1 | 0.140 |
Why?
| Immune Tolerance | 1 | 2015 | 8 | 0.140 |
Why?
| Infant Formula | 1 | 2015 | 15 | 0.140 |
Why?
| Pediatric Obesity | 1 | 2018 | 128 | 0.140 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2015 | 1 | 0.140 |
Why?
| Electrodiagnosis | 2 | 2006 | 4 | 0.140 |
Why?
| C-Reactive Protein | 1 | 1995 | 16 | 0.140 |
Why?
| Ghrelin | 1 | 2015 | 2 | 0.130 |
Why?
| Psychology, Child | 2 | 2012 | 12 | 0.130 |
Why?
| Colitis | 1 | 2015 | 13 | 0.130 |
Why?
| Hydrochloric Acid | 1 | 1994 | 1 | 0.130 |
Why?
| Hydroxyindoleacetic Acid | 1 | 1994 | 1 | 0.130 |
Why?
| Apnea | 1 | 1994 | 5 | 0.130 |
Why?
| Critical Illness | 1 | 1994 | 22 | 0.130 |
Why?
| Allergens | 1 | 2015 | 56 | 0.130 |
Why?
| Anti-Inflammatory Agents | 2 | 2013 | 11 | 0.130 |
Why?
| Health Care Surveys | 1 | 2014 | 33 | 0.130 |
Why?
| Permeability | 1 | 2014 | 7 | 0.130 |
Why?
| Edema | 2 | 2015 | 8 | 0.120 |
Why?
| Biomarkers | 2 | 2015 | 123 | 0.120 |
Why?
| Illness Behavior | 1 | 2013 | 2 | 0.120 |
Why?
| Sick Role | 1 | 2013 | 3 | 0.120 |
Why?
| Adalimumab | 1 | 2013 | 2 | 0.120 |
Why?
| Remission Induction | 1 | 2013 | 25 | 0.120 |
Why?
| Endoscopy | 1 | 2013 | 15 | 0.120 |
Why?
| Asthma | 1 | 1995 | 143 | 0.120 |
Why?
| Parenting | 1 | 2013 | 24 | 0.110 |
Why?
| Parent-Child Relations | 1 | 2013 | 33 | 0.110 |
Why?
| Interprofessional Relations | 1 | 2012 | 6 | 0.110 |
Why?
| Affective Symptoms | 1 | 2012 | 3 | 0.110 |
Why?
| Cooperative Behavior | 1 | 2012 | 26 | 0.110 |
Why?
| Socioeconomic Factors | 2 | 2006 | 63 | 0.110 |
Why?
| Gastric Fundus | 1 | 1992 | 3 | 0.110 |
Why?
| Fecal Impaction | 1 | 2012 | 3 | 0.110 |
Why?
| Laxatives | 1 | 2012 | 5 | 0.110 |
Why?
| Cathartics | 1 | 2012 | 4 | 0.110 |
Why?
| Emergencies | 1 | 2012 | 11 | 0.110 |
Why?
| Enema | 1 | 2012 | 14 | 0.110 |
Why?
| Polyethylene Glycols | 1 | 2012 | 12 | 0.110 |
Why?
| Vomiting | 3 | 2020 | 24 | 0.100 |
Why?
| Sex Factors | 3 | 2007 | 78 | 0.100 |
Why?
| Mucositis | 1 | 2010 | 2 | 0.100 |
Why?
| Satiation | 1 | 2010 | 3 | 0.100 |
Why?
| Education, Graduate | 1 | 1990 | 1 | 0.100 |
Why?
| Occupational Health Services | 1 | 1990 | 1 | 0.100 |
Why?
| Nutritional Sciences | 1 | 1990 | 2 | 0.100 |
Why?
| Sleep Initiation and Maintenance Disorders | 2 | 2012 | 7 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 2 | 2009 | 95 | 0.100 |
Why?
| Patch Tests | 1 | 2010 | 2 | 0.090 |
Why?
| Single-Blind Method | 1 | 2010 | 13 | 0.090 |
Why?
| ROC Curve | 1 | 2010 | 18 | 0.090 |
Why?
| Odds Ratio | 1 | 2010 | 53 | 0.090 |
Why?
| Immunoglobulin G | 1 | 2010 | 33 | 0.090 |
Why?
| Feasibility Studies | 2 | 2020 | 67 | 0.090 |
Why?
| North America | 1 | 2010 | 47 | 0.090 |
Why?
| Terminology as Topic | 1 | 2010 | 14 | 0.090 |
Why?
| Data Collection | 1 | 2010 | 32 | 0.090 |
Why?
| Health Education | 1 | 1990 | 39 | 0.090 |
Why?
| Attitude of Health Personnel | 1 | 2010 | 50 | 0.090 |
Why?
| Accelerometry | 2 | 2019 | 44 | 0.090 |
Why?
| Dietary Fats | 1 | 1989 | 8 | 0.090 |
Why?
| Mucocutaneous Lymph Node Syndrome | 1 | 1989 | 9 | 0.090 |
Why?
| Gallbladder Diseases | 1 | 1989 | 13 | 0.090 |
Why?
| Predictive Value of Tests | 3 | 1995 | 104 | 0.080 |
Why?
| Mice, Inbred C57BL | 2 | 2019 | 89 | 0.080 |
Why?
| Mechanotransduction, Cellular | 1 | 2008 | 5 | 0.080 |
Why?
| Reproducibility of Results | 3 | 2019 | 201 | 0.080 |
Why?
| Parents | 2 | 2008 | 152 | 0.080 |
Why?
| Fasting | 1 | 2006 | 4 | 0.070 |
Why?
| Gallbladder | 1 | 2006 | 3 | 0.070 |
Why?
| Young Adult | 2 | 2019 | 665 | 0.070 |
Why?
| Reference Values | 1 | 2006 | 41 | 0.070 |
Why?
| Biliary Dyskinesia | 1 | 2006 | 8 | 0.070 |
Why?
| Hydroxyzine | 1 | 2006 | 1 | 0.070 |
Why?
| Ranitidine | 1 | 2006 | 5 | 0.070 |
Why?
| Drug Therapy, Combination | 1 | 2006 | 41 | 0.070 |
Why?
| Cross-Over Studies | 2 | 2004 | 32 | 0.070 |
Why?
| Psychology | 1 | 2006 | 6 | 0.070 |
Why?
| Education, Medical, Continuing | 1 | 2006 | 6 | 0.070 |
Why?
| China | 2 | 2015 | 8 | 0.070 |
Why?
| Missouri | 1 | 2006 | 78 | 0.070 |
Why?
| Endoscopy, Gastrointestinal | 2 | 2015 | 20 | 0.070 |
Why?
| Risk Assessment | 1 | 2006 | 137 | 0.070 |
Why?
| Infusions, Parenteral | 1 | 2004 | 5 | 0.060 |
Why?
| Safety | 1 | 2004 | 14 | 0.060 |
Why?
| Colitis, Ulcerative | 1 | 2004 | 10 | 0.060 |
Why?
| Clavicle | 1 | 2004 | 1 | 0.060 |
Why?
| Osteomyelitis | 1 | 2004 | 6 | 0.060 |
Why?
| Double-Blind Method | 1 | 2004 | 49 | 0.060 |
Why?
| Factor Analysis, Statistical | 2 | 2013 | 24 | 0.060 |
Why?
| Posture | 2 | 1994 | 9 | 0.060 |
Why?
| Administration, Oral | 2 | 2012 | 62 | 0.060 |
Why?
| Psychometrics | 2 | 2013 | 33 | 0.060 |
Why?
| Phobic Disorders | 1 | 2022 | 4 | 0.060 |
Why?
| Disability Evaluation | 1 | 2022 | 10 | 0.060 |
Why?
| Aspartate Aminotransferases | 1 | 2022 | 4 | 0.060 |
Why?
| Alanine Transaminase | 1 | 2022 | 5 | 0.060 |
Why?
| Chi-Square Distribution | 2 | 2012 | 34 | 0.050 |
Why?
| Individuality | 1 | 2021 | 2 | 0.050 |
Why?
| Effect Modifier, Epidemiologic | 1 | 2021 | 2 | 0.050 |
Why?
| Body Mass Index | 1 | 2022 | 156 | 0.050 |
Why?
| Liver | 1 | 2022 | 139 | 0.050 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 9 | 0.040 |
Why?
| Age Distribution | 1 | 2019 | 32 | 0.040 |
Why?
| Delivery of Health Care, Integrated | 1 | 2019 | 9 | 0.040 |
Why?
| Acute Disease | 1 | 2019 | 71 | 0.040 |
Why?
| Databases as Topic | 1 | 2019 | 2 | 0.040 |
Why?
| HEK293 Cells | 1 | 2019 | 31 | 0.040 |
Why?
| Prenatal Care | 1 | 1999 | 4 | 0.040 |
Why?
| Maternal-Child Nursing | 1 | 1998 | 1 | 0.040 |
Why?
| Employment | 1 | 1998 | 4 | 0.040 |
Why?
| Interviews as Topic | 1 | 1999 | 36 | 0.040 |
Why?
| Infant Food | 1 | 1998 | 7 | 0.040 |
Why?
| Mother-Child Relations | 1 | 1998 | 5 | 0.040 |
Why?
| Patient Discharge | 1 | 2019 | 60 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2019 | 87 | 0.040 |
Why?
| Milk, Human | 1 | 1998 | 21 | 0.040 |
Why?
| Drug Dosage Calculations | 1 | 2018 | 17 | 0.040 |
Why?
| Patient Education as Topic | 1 | 1999 | 64 | 0.040 |
Why?
| Jaw | 1 | 2018 | 2 | 0.040 |
Why?
| Radiography, Panoramic | 1 | 2018 | 3 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 2019 | 102 | 0.040 |
Why?
| Cytochrome P-450 CYP2C19 | 1 | 2018 | 55 | 0.040 |
Why?
| Oxidative Stress | 1 | 2018 | 14 | 0.040 |
Why?
| Signal Transduction | 1 | 2019 | 111 | 0.040 |
Why?
| Length of Stay | 1 | 2019 | 243 | 0.040 |
Why?
| Mice, Knockout | 1 | 2018 | 58 | 0.040 |
Why?
| Pregnancy | 1 | 1999 | 271 | 0.040 |
Why?
| Stomatitis | 1 | 1997 | 1 | 0.040 |
Why?
| Oral Ulcer | 1 | 1997 | 1 | 0.040 |
Why?
| Genotype | 1 | 2018 | 401 | 0.040 |
Why?
| Mice | 1 | 2018 | 312 | 0.040 |
Why?
| Mutation | 1 | 2018 | 199 | 0.040 |
Why?
| Recurrence | 2 | 2008 | 123 | 0.040 |
Why?
| Down-Regulation | 1 | 2016 | 16 | 0.040 |
Why?
| Parenteral Nutrition, Total | 1 | 1996 | 7 | 0.040 |
Why?
| Microfilament Proteins | 1 | 2016 | 14 | 0.040 |
Why?
| Hypoalbuminemia | 1 | 2015 | 4 | 0.040 |
Why?
| Milk | 1 | 2015 | 6 | 0.040 |
Why?
| Cattle | 1 | 2015 | 25 | 0.040 |
Why?
| Failure to Thrive | 1 | 2015 | 7 | 0.030 |
Why?
| Syndrome | 1 | 2015 | 33 | 0.030 |
Why?
| Malnutrition | 1 | 2015 | 9 | 0.030 |
Why?
| Physical Therapy Modalities | 1 | 1995 | 4 | 0.030 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2015 | 15 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2016 | 46 | 0.030 |
Why?
| Neoplasms | 1 | 1998 | 120 | 0.030 |
Why?
| Hypoglycemia | 1 | 1996 | 26 | 0.030 |
Why?
| Bronchodilator Agents | 1 | 1995 | 11 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2015 | 46 | 0.030 |
Why?
| Fluid Therapy | 1 | 1995 | 21 | 0.030 |
Why?
| Sodium Acetate | 1 | 2015 | 2 | 0.030 |
Why?
| Carbon Isotopes | 1 | 2015 | 4 | 0.030 |
Why?
| Eosinophilic Esophagitis | 1 | 2015 | 3 | 0.030 |
Why?
| Regression Analysis | 1 | 1995 | 56 | 0.030 |
Why?
| Wakefulness | 1 | 1994 | 2 | 0.030 |
Why?
| Blood Gas Analysis | 1 | 1994 | 6 | 0.030 |
Why?
| Causality | 1 | 1994 | 10 | 0.030 |
Why?
| Proxy | 1 | 2013 | 2 | 0.030 |
Why?
| Principal Component Analysis | 1 | 2013 | 13 | 0.030 |
Why?
| Interpersonal Relations | 1 | 2012 | 13 | 0.030 |
Why?
| Social Participation | 1 | 2012 | 2 | 0.030 |
Why?
| Psychiatric Status Rating Scales | 1 | 2012 | 16 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 1995 | 244 | 0.030 |
Why?
| Adaptation, Psychological | 1 | 2012 | 41 | 0.030 |
Why?
| Evaluation Studies as Topic | 1 | 1992 | 7 | 0.030 |
Why?
| Molasses | 1 | 2012 | 2 | 0.030 |
Why?
| Osmosis | 1 | 2012 | 2 | 0.030 |
Why?
| Schools | 1 | 2012 | 50 | 0.030 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 81 | 0.030 |
Why?
| Feces | 1 | 2012 | 37 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2005 | 82 | 0.030 |
Why?
| Patient Readmission | 1 | 2012 | 68 | 0.030 |
Why?
| Erythroblastosis, Fetal | 1 | 1989 | 2 | 0.020 |
Why?
| Jaundice | 1 | 1989 | 4 | 0.020 |
Why?
| Abdomen | 1 | 1989 | 14 | 0.020 |
Why?
| Self Disclosure | 1 | 2008 | 6 | 0.020 |
Why?
| Social Behavior | 1 | 2008 | 12 | 0.020 |
Why?
| Bronchopulmonary Dysplasia | 1 | 1989 | 41 | 0.020 |
Why?
| Emotions | 1 | 2008 | 23 | 0.020 |
Why?
| Cluster Analysis | 1 | 2008 | 45 | 0.020 |
Why?
| Child Behavior | 1 | 2008 | 30 | 0.020 |
Why?
| Heart Defects, Congenital | 1 | 1989 | 82 | 0.020 |
Why?
| Diagnostic Techniques, Digestive System | 1 | 2007 | 5 | 0.020 |
Why?
| Anthropometry | 1 | 2007 | 17 | 0.020 |
Why?
| Tryptases | 1 | 2006 | 1 | 0.020 |
Why?
| Cholecystectomy | 1 | 2006 | 8 | 0.020 |
Why?
| Serine Endopeptidases | 1 | 2006 | 5 | 0.020 |
Why?
| Hypnotics and Sedatives | 1 | 2005 | 5 | 0.020 |
Why?
| Indiana | 1 | 1998 | 1 | 0.010 |
Why?
| Cysteine Endopeptidases | 1 | 1998 | 2 | 0.010 |
Why?
| Fluorescence | 1 | 1998 | 5 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 1998 | 24 | 0.010 |
Why?
| Clobetasol | 1 | 1997 | 1 | 0.010 |
Why?
| Sarcoidosis | 1 | 1997 | 1 | 0.010 |
Why?
| Administration, Topical | 1 | 1997 | 6 | 0.010 |
Why?
| Glucocorticoids | 1 | 1997 | 30 | 0.010 |
Why?
| Kinetics | 1 | 1996 | 30 | 0.010 |
Why?
| Blood Glucose | 1 | 1996 | 59 | 0.010 |
Why?
| Insulin | 1 | 1996 | 50 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|